Bempedoic Acid / Ezetimibe FDC (NEXLIZET)
Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH)
ApprovedCommercial
Key Facts
Indication
Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH)
Phase
Approved
Status
Commercial
Company
About Esperion Therapeutics (2)
Esperion Therapeutics has successfully transitioned from a research entity to a commercial company with two FDA-approved products: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). Its strategy centers on maximizing the U.S. commercial potential of its oral, non-statin LDL-lowering franchise while leveraging international partnerships for global reach. The company's core achievement is establishing a new therapeutic class with a differentiated mechanism designed to avoid muscle-related side effects, targeting the vast population of patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).
View full company profileTherapeutic Areas
Other Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH) Drugs
| Drug | Company | Phase |
|---|---|---|
| Bempedoic Acid (NEXLETOL) | Esperion Therapeutics (2) | Approved |